ABODE Study for Neoadjuvant Chemotherapy Patients
The University Health Network in Toronto is preparing the ABODE study to evaluate patient activation during neoadjuvant chemotherapy.
The ABODE Study for Patients Undergoing Neoadjuvant Chemotherapy is currently listed as not yet recruiting, according to a ClinicalTrials.gov registry observation published on November 20, 2026. Sponsored by the University Health Network in Toronto, this clinical research project aims to investigate patient experiences during neoadjuvant chemotherapy, which is treatment provided before a primary treatment like surgery.
The study is designed as a randomized trial. Participants will be assigned to either an experimental group that uses a specific application or a control group that receives no intervention. While the study has not yet begun enrolling participants, the estimated primary completion date for the research is set for October 2028.
Measuring Patient Activation
A central focus of the ABODE study is the measurement of patient activation. Researchers plan to use the Patient Activation Measure 13 (PAM-13), which is a 13-item scale used to assess a person's self-reported knowledge, skills, and confidence regarding the self-management of their own health and healthcare.
The study will collect data on these activation levels at several specific intervals. Measurements are scheduled for baseline, 3 months post-baseline, 3 months post-operation, and 12 months post-baseline. Each item on the PAM-13 scale is rated using a 4-point Likert scale, ranging from 1 for strongly disagree to 4 for strongly agree.
Study Timeline and Status
As of the November 2026 registry update, the study has not yet produced any results. The current status remains in the pre-recruitment phase, meaning the clinical trial is being prepared but has not yet started the process of enrolling patients into the randomized arms.
The research is part of a broader landscape of medical developments, including those tracked under the Cancer Breakthroughs event. Because the primary completion is an estimate, the final timeline for the study's conclusion remains subject to the progress of the clinical investigation.